DIA
SAGE

Denver Investment Advisors’s Sage Therapeutics SAGE Stock Holding History

Denver Investment Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-4,403
Closed -$351K – 457
2017
Q2 		$351K Sell
4,403
-2,020
-31% -$146K 0.02% 364
2017
Q1 		$456K Sell
6,423
-200
-3% -$11.7K 0.02% 342
2016
Q4 		$338K Buy
+6,623
New +$312K 0.01% 397
2015
Q2 		– Sell
-61,141
Closed -$3.07M – 604
2015
Q1 		$3.07M Buy
61,141
+28,940
+90% +$1.24M 0.1% 220
2014
Q4 		$1.18M Buy
+32,201
New +$1.2M 0.04% 342

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Denver Investment Advisors's SAGE Position: Q3 2017 in Review

Denver Investment Advisors sold out of Sage Therapeutics (SAGE) in Q3 2017, closing a stake of 4,403 shares — an estimated $351K sold.

Denver Investment Advisors first reported a position in SAGE in Q4 2014 and held it in 5 quarters. The position peaked at $3.07M in Q1 2015. 174 funds tracked by Wall St. Rank hold SAGE as of Q3 2017.

  • Denver Investment Advisors reported no remaining Sage Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Denver Investment Advisors sold 4,403 Sage Therapeutics shares in Q3 2017, an estimated $351K.
  • Denver Investment Advisors first reported a position in Sage Therapeutics in Q4 2014 and held it in 5 quarters.
  • Denver Investment Advisors's Sage Therapeutics position peaked at $3.07M in Q1 2015.
  • 174 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2017.

Based on Denver Investment Advisors's 13F filing for Q3 2017, filed 13 Nov 2017.